IP Library Granted Patent US 11,434,257
Granted Patent B2
US 11,434,257 · App. 16/777,253 · Granted Sep 6, 2022

Aminosteroids for the treatment of a PTP1B associated disease

Inventors: Michael McLane (Lansdale, PA); Inez Ruiz-White (Mount Laurel, NJ); W. Lee Maloy (Lansdale, PA); Henry R. Wolfe (Glenmoore, PA)
Assignee: DepYmed Inc.
C07J41/0005C07J41/005C07J41/0055C07J43/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,434,257
App. No.
16/777,253
Granted
Sep 6, 2022
Kind
B2
Abstract

This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Claims (13)

1. A compound or pharmaceutically acceptable salt thereof selected from the group consisting of:

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable diluent or a pharmaceutically acceptable carrier.

3. A method of inhibiting protein tyrosine phosphatase PTP1B in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. A compound of formula

or a pharmaceutically acceptable salt thereof,

wherein:

X 2 =—OH or H;

X 3 =H, —OH;

X 4 =—OH or H; and

X 5 =H or —CH 3 ; provided at least one of X 2 or X 3 is OH.

5. A method of inhibiting protein tyrosine phosphatase PTP1B in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 4 , or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein inhibiting protein tyrosine phosphatase PTP1B in a mammal treats diabetes.

7. A pharmaceutical composition comprising a compound of claim 4 , and a pharmaceutically acceptable diluent or a pharmaceutically acceptable carrier.

Assignments (2)
MERGER Recorded May 24, 2021
From: OHR PHARMACEUTICAL, INC.
To: NEUBASE THERAPEUTICS INC.
Reel/Frame 056328/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2021
From: NEUBASE THERAPEUTICS INC.
To: DEPYMED INC.
Reel/Frame 056328/0189 →
Continuity (5)
Continuation 16299872 · Mar 12, 2019
Continuation 15286646 · Oct 6, 2016
Continuation 14394789
Provisional Application 61636252 · Apr 20, 2012
Related Publication 20200270300A1 · Aug 27, 2020